GlassScriptPhysician profile
Sara Andolina
NPI 1194142570
$9,412.12
in general payments reported to CMS, 2019-2025
24 companies · $2,944 in 2025
The $2,944 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $811 · 2022: $1,583 · 2023: $2,076 · 2024: $1,997 · 2025: $2,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,758 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,757.57 |
| Education | $259.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,398.56 | 2021-2025 | |
| Janssen Biotech, INC. | $1,344.05 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,271.64 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $474.46 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $459.15 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $451.67 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $355.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $332.09 | 2022-2023 | Zeposia |
| Genzyme Corporation | $233.00 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $231.35 | 2022-2025 | Ocaliva |
| Celltrion USA INC. | $217.47 | 2025 | Zymfentra, Vegzelma |
| Lilly USA, LLC | $205.77 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $81.22 | 2024-2025 | Voquezna |
| Amgen INC. | $61.83 | 2021 | |
| Enterra Medical, INC. | $52.87 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $49.25 | 2023-2025 | |
| Braintree Laboratories, INC. | $36.72 | 2025 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $33.98 | 2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $26.63 | 2021-2022 | |
| Novo Nordisk INC | $24.35 | 2025 | Wegovy |
| Intra-Sana Laboratories | $19.47 | 2021 | |
| Pinnacle Biologics, INC | $18.82 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.03 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.34 | 2025 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Andolina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.